title: Photorefractive keratectomy in high myopic defects with or without intraoperative mitomycin C: 1-year results.
abstract: OBJECTIVE
  To study the results of the prophylactic use of mitomycin C (MMC) to reduce haze formation and refractive regression after excimer laser photorefractive keratectomy (PRK) for high myopic defects (>5 diopters).
  
  
  METHODS
  Prospective, consecutive, observational study. A total of 124 eyes of 62 patients were divided into two groups of 31 patients, 62 eyes each (Groups A and B). Only Group A was treated with MMC 0.02%. The data of the two groups of eyes, related to the best-corrected visual acuity (BCVA), to the difference of refraction pre- and post-treatment, and to the corneal haze, were analyzed through combined permutation tests by using the NPC Test software .
  
  
  RESULTS
  BCVA of Group A, 1 year after treatment, was better than that of the control Group B (one-sided p value = 0.013): Group A - 3 eyes (4.8%) had a loss of a decimal fraction and no eyes > 1; Group B - 13 eyes (20.9%) had a loss of a decimal fraction and 1 eye (1.6%) of 2. There was a smaller difference between attempted and achieved SE correction in Group A with respect to Group B (one-sided p value = 0.068): Group A - 43 eyes (69.3%) within +/- 0.50 D; Group B - 31 eyes (50%) within +/- 0.50 D. there was a smaller incidence of corneal haze in the group for which MMC was used (one-sided p value = 0.005).
  
  
  CONCLUSIONS
  In this study, the application of MMC 0.02% solution immediately after PRK produced lower haze rates and had better predictability and improved efficacy 1 year after treatment.
authors.affiliation: H.M.O. M.D. Barbantini, Lucca, Italy. abedei@tiscali.it
authors.forename: A
authors.initials: A
authors.lastname: Bedei
authors.forename: A
authors.initials: A
authors.lastname: Marabotti
authors.forename: I
authors.initials: I
authors.lastname: Giannecchini
authors.forename: C
authors.initials: C
authors.lastname: Ferretti
authors.forename: M
authors.initials: M
authors.lastname: Montagnani
authors.forename: C
authors.initials: C
authors.lastname: Martinucci
authors.forename: L
authors.initials: L
authors.lastname: Barabesi
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001251:Astigmatism / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery; D003131:Combined Modality Therapy; D003319:Corneal Stroma / Q000187:drug effects / Q000601:surgery; D005260:Female; D006801:Humans; D007430:Intraoperative Care / Q000379:methods; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009216:Myopia / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D018903:Photorefractive Keratectomy / Q000379:methods*; D011446:Prospective Studies; D012029:Refraction, Ocular / Q000502:physiology; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014945:Wound Healing / Q000502:physiology
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin